The Board meeting is scheduled to be held on Wednesday, July 15, 2026. The primary agenda item is to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2026 (Q1 FY2027).
The Company has implemented a 'Trading Window' closure for dealing in the securities of the Company by its Designated Persons and their immediate relatives. The trading window has been closed from July 1, 2026 and will remain closed until 48 hours after the declaration of the aforementioned Unaudited Financial Results.
This intimation has been made available on the company's website at www.sardaproteins.in.